Visudyne (黃斑部水腫·黃斑部病變治療藥) - 2023年前的預測與市場分析
Visudyne (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 78 Pages
|Visudyne (黃斑部水腫·黃斑部病變治療藥) - 2023年前的預測與市場分析 Visudyne (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023|
|出版日期: 2014年10月31日||內容資訊: 英文 78 Pages||
本報告提供黃斑部水腫及黃斑部病變治療藥物──Visudyne (verteporfin) 之相關調查，提供您黃斑部水腫及黃斑部病變概要和治療藥的競爭趨勢，產品資訊，銷售額預測等資訊。
Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.
Visudyne (verteporfin) is a photosensitizer molecule that was co-developed by QLT PhotoTherapeutics and Novartis Pharma AG for use in a two-step procedure involving the use of a non-thermal laser light, known as PDT. It was initially approved by the FDA in April 2000 for the treatment of patients with predominantly classical subfoveal CNV due to AMD.